Evidence map›Paper›PMID 23900841›Full record

ArticleThe Journal of biological chemistry2013

Heat shock proteins regulate activation-induced proteasomal degradation of the mature phosphorylated form of protein kinase C.

Michelle A Lum, Gregor M Balaburski, Maureen E Murphy, Adrian R Black, Jennifer D Black

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. The complexities of PKCα signaling in cancer.Advances in biological regulation · 2021
    Review
  4. Review
  5. Review
  6. Frontiers in cellular and infection microbiology · 2017
    Review
  7. Article
  8. Review
  9. Tuning the signalling output of protein kinase C.Biochemical Society transactions · 2014
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Michelle A LumFrom The Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950; Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263.
Gregor M BalaburskiWistar Institute, Philadelphia, Pennsylvania 19104.
Maureen E MurphyWistar Institute, Philadelphia, Pennsylvania 19104.
Adrian R BlackFrom The Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950; Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263.
Jennifer D BlackFrom The Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950; Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263. Electronic address: jennifer.black@unmc.edu.
The Wistar Institute · USUniversity of Nebraska Medical Center · USRoswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
The ARF Tumor SuppressorR01CA139319 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2010 to 2019
$3.9M
REGULATION OF CYCLIN D1 EXPRESSION IN THE INTESTINER01DK060632 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BLACK, JENNIFER D. · 2002 to 2014
$2.6M
PKC ISOZYMES AND INTESTINAL EPITHELIAL GROWTH CONTROLR01DK054909 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BLACK, JENNIFER D. · 1999 to 2009
$2.1M
Regulation of cyclin D1 expression in the intestineR56DK060632 · NIDDK · ROSWELL PARK CANCER INSTITUTE CORP · PI BLACK, JENNIFER D. · 2009 to 2009
$373k
NCI NIH HHS CA036727NCI NIH HHS CA16056NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA139319NIDDK NIH HHS DK54909NIDDK NIH HHS DK60632NIDDK NIH HHS R01 DK054909NIDDK NIH HHS R01 DK060632NIDDK NIH HHS R56 DK060632
6 · The paper itself

Abstract

Although alterations in stimulus-induced degradation of PKC have been implicated in disease, mechanistic understanding of this process remains limited. Evidence supports the existence of both proteasomal and lysosomal mechanisms of PKC processing. An established pathway involves rate-limiting priming site dephosphorylation of the activated enzyme and proteasomal clearance of the dephosphorylated protein. However, here we show that agonists promote down-regulation of endogenous PKCα with minimal accumulation of a nonphosphorylated species in multiple cell types. Furthermore, proteasome and lysosome inhibitors predominantly protect fully phosphorylated PKCα, pointing to this form as a substrate for degradation. Failure to detect substantive dephosphorylation of activated PKCα was not due to rephosphorylation because inhibition of Hsp70/Hsc70, which is required for re-priming, had only a minor effect on agonist-induced accumulation of nonphosphorylated protein. Thus, PKC degradation can occur in the absence of dephosphorylation. Further analysis revealed novel functions for Hsp70/Hsc70 and Hsp90 in the control of agonist-induced PKCα processing. These chaperones help to maintain phosphorylation of activated PKCα but have opposing effects on degradation of the phosphorylated protein; Hsp90 is protective, whereas Hsp70/Hsc70 activity is required for proteasomal processing of this species. Notably, down-regulation of nonphosphorylated PKCα shows little Hsp70/Hsc70 dependence, arguing that phosphorylated and nonphosphorylated species are differentially targeted for proteasomal degradation. Finally, lysosomal processing of activated PKCα is not regulated by phosphorylation or Hsps. Collectively, these data demonstrate that phosphorylated PKCα is a direct target for agonist-induced proteasomal degradation via an Hsp-regulated mechanism, and highlight the existence of a novel pathway of PKC desensitization in cells.

Indexed as

ProteolysisAnimalsHeat-Shock ProteinsHeLa CellsHumansLysosomesPhosphorylationProteasome Endopeptidase ComplexProtein Kinase C-alphaRatsHeat-Shock ProteinsPRKCA protein, humanProteasome Endopeptidase ComplexProtein Kinase C-alphaHeat Shock ProteinHsp70/Hsc70Hsp90Lysosomal DegradationPhosphorylationPKCαProteasomal DegradationProtein DegradationProtein Kinase C (PKC)

Identifiers

PMID23900841
PMCPMC3779710
OpenAlexW2013978920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.